Evogene Ltd. (NASDAQ:EVGN – Get Free Report) saw a significant decrease in short interest during the month of October. As of October 15th, there was short interest totaling 63,883 shares, a decrease of 93.2% from the September 30th total of 932,725 shares. Approximately 0.8% of the company’s stock are sold short. Based on an average daily volume of 244,058 shares, the short-interest ratio is currently 0.3 days.
Insiders Place Their Bets
In related news, Director Leon Recanati acquired 460,000 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were bought at an average price of $0.64 per share, with a total value of $294,400.00. Following the completion of the acquisition, the director owned 1,343,886 shares in the company, valued at $860,087.04. This trade represents a 52.04% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 7.40% of the company’s stock.
Analyst Ratings Changes
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Evogene in a report on Friday, October 2nd. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock currently has an average rating of “Sell”.
Check Out Our Latest Analysis on Evogene
Evogene Stock Performance
NASDAQ EVGN traded up $0.01 during trading hours on Monday, hitting $0.37. The company had a trading volume of 39,606 shares, compared to its average volume of 3,672,514. The business has a 50 day moving average of $0.47 and a 200-day moving average of $0.68. Evogene has a 1-year low of $0.35 and a 1-year high of $1.33.
About Evogene
Evogene Ltd. is an Israel-based computational biology company that develops products and technologies for the life sciences and agriculture industries. Founded in 1999 and headquartered in Rehovot, Israel, the company uses its Computational Predictive Biology platform, which combines biological data, artificial intelligence and machine-learning tools to identify and develop novel biological products.
Evogene’s activities have included agricultural solutions such as crop-protection products, bio-stimulants and microbiome-based technologies.
See Also
- Five stocks we like better than Evogene
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
